Company intelligence / Profile preview

SynerK

Suzhou, Jiangsu Province, Chinasynerk.cn ↗

Ownership: Private
Development stage: Other

Overview

SynerK is developing a pipeline of RNA-targeted therapeutics. Its lead programs include SNK‑396, currently in Phase 1 for lipid disorders, and SNK‑2726, an siRNA drug targeting angiotensinogen for hypertension that is at the IND filing preparation stage. The company has formed a strategic partnership with Huadong Medicine to co-develop SNK‑2726 and leverage its GalNexus siRNA platform technology. Other pipeline assets target various cancers.

Therapeutic areas: OncologyCardiovascular
Modalities: Small nucleic acid drugs (including siRNA)RNA-targeted therapies
Industry: Biotech

Partnerships

Huadong Medicine Co., Ltd.: Strategic partnership for joint development of SNK‑2726 with exclusive option rights for Greater China.

Beyond the preview

Go deeper on SynerK.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SynerK.